Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.

Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a complex interplay between genetics and environment. The autoimmune destruction, often associated with a virally induced or inflammatory response, progresses over months to years, leading to significant loss of β cell mass and function. Hyperglycemia manifests once a critical threshold of β cell destruction is surpassed, signifying the clinical onset of the disease.

Type 2 diabetes differs markedly from type 1, encompassing a heterogeneous syndrome with roots in insulin resistance and impaired insulin secretion. Typically associated with obesity, and having a gradual onset, there is a strong genetic predisposition. Insulin resistance prevents efficient glucose uptake, and skeletal muscle, adipose tissue, and the liver are pivotal to its development. Elevated fasting insulin levels, increased circulatory proinsulin proportions, and dysregulated glucagon secretion complicate the condition. Intrinsic and extrinsic factors such as aging, lifestyle, and intra-abdominal fat contribute to insulin sensitivity variations.

Other forms of diabetes include monogenic forms of diabetes, such as MODY and neonatal diabetes, which arise from mutations affecting key genes in glucose regulation, presenting a range of clinical features. These can often mimic type 1 or type 2 diabetes but have distinct genetic underpinnings, necessitating tailored treatments. Additionally, diseases like pancreatitis or cystic fibrosis and certain endocrinopathies can induce secondary forms of diabetes by disrupting normal glucose metabolism.

Gestational diabetes is glucose intolerance which occurs during pregnancy. Physiologically, it's driven by placental hormones causing insulin resistance to ensure a steady glucose supply to the growing fetus. In most cases, the mother's pancreas compensates by producing more insulin. However, when insulin production is insufficient, gestational diabetes ensues. Though it typically resolves after childbirth, it increases the risk for type 2 diabetes in both mother and child in the future.

Each form of diabetes exhibits unique pathophysiological characteristics, necessitating individualized approaches to monitoring and treatment to manage the abnormal glucose homeostasis central to the disease.

Do Capítulo 25:

article

Now Playing

25.4 : Pathophysiology of Diabetes

Insulin and Hypoglycemic Drugs

513 Visualizações

article

25.1 : Homeostase da glicose: regulação da glicose no sangue

Insulin and Hypoglycemic Drugs

918 Visualizações

article

25.2 : Homeostase da glicose: ilhotas pancreáticas e secreção de insulina

Insulin and Hypoglycemic Drugs

661 Visualizações

article

25.3 : Insulina: o receptor e as vias de sinalização

Insulin and Hypoglycemic Drugs

717 Visualizações

article

25.5 : Diabetes: sintomas, diagnóstico e complicações

Insulin and Hypoglycemic Drugs

383 Visualizações

article

25.6 : Diabetes: Manejo e Farmacoterapia

Insulin and Hypoglycemic Drugs

148 Visualizações

article

25.7 : Insulina: Biossíntese, Química e Preparação

Insulin and Hypoglycemic Drugs

164 Visualizações

article

25.8 : Formulações de insulina: tipos e administração

Insulin and Hypoglycemic Drugs

79 Visualizações

article

25.9 : Insulina: Regime de dosagem e efeitos adversos

Insulin and Hypoglycemic Drugs

64 Visualizações

article

25.10 : Hipoglicemiantes orais: sulfonilureias

Insulin and Hypoglycemic Drugs

78 Visualizações

article

25.11 : Hipoglicemiantes orais: biguanidas e glitazonas

Insulin and Hypoglycemic Drugs

83 Visualizações

article

25.12 : Hipoglicemiantes orais: glinetos

Insulin and Hypoglycemic Drugs

57 Visualizações

article

25.13 : Agentes hipoglicemiantes orais: inibidores da α-glicosidase

Insulin and Hypoglycemic Drugs

61 Visualizações

article

25.14 : Agonistas do receptor semelhante ao glucagon

Insulin and Hypoglycemic Drugs

114 Visualizações

article

25.15 : Inibidores da dipeptidil peptidase 4

Insulin and Hypoglycemic Drugs

57 Visualizações

See More

JoVE Logo

Privacidade

Termos de uso

Políticas

Pesquisa

Educação

SOBRE A JoVE

Copyright © 2025 MyJoVE Corporation. Todos os direitos reservados